Innoviva to Sell Basilea Pharmaceutica's MRSA Antibiotic Zevtera in US Under Exclusive Deal

MT Newswires Live2024-12-16

Innoviva (INVA) unit Innoviva Specialty Therapeutics said Monday it signed an exclusive licensing and distribution deal with Basilea Pharmaceutica for US marketing rights to the antibiotic Zevtera or ceftobiprole.

The company, which plans to launch Zevtera in the US by mid-2025, said it will pay Basilea $4 million upfront, with additional royalties and sales milestones.

Basilea said in a separate statement that it expects to receive sales milestones of up to $223 million.

Zevtera, approved by the US Food and Drug Administration in April, is the only cephalosporin cleared for treating methicillin-resistant Staphylococcus aureus, or MRSA, bloodstream infections and endocarditis in adults.

The drug is also approved for other bacterial infections, including skin infections in adults and pneumonia in patients aged three months to 18 years, the company said.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2491962606?lang=en_US&edition=full_marsco","thumbnail":"","is_english":true,"pubTime":"2024-12-16 21:40","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2491962606","market":"hk","top_or_hot":-1,"title":"Innoviva to Sell Basilea Pharmaceutica's MRSA Antibiotic Zevtera in US Under Exclusive Deal","media":"MT Newswires Live","content":"<html><body><p> Innoviva (INVA) unit Innoviva Specialty <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> said Monday it signed an exclusive licensing and distribution deal with Basilea Pharmaceutica for US marketing rights to the antibiotic Zevtera or ceftobiprole.</p><p>The company, which plans to launch Zevtera in the US by mid-2025, said it will pay Basilea $4 million upfront, with additional royalties and sales milestones.</p><p>Basilea said in a separate statement that it expects to receive sales milestones of up to $223 million.</p><p>Zevtera, approved by the US Food and Drug Administration in April, is the only cephalosporin cleared for treating methicillin-resistant Staphylococcus aureus, or MRSA, bloodstream infections and endocarditis in adults.</p><p>The drug is also approved for other bacterial infections, including skin infections in adults and pneumonia in patients aged three months to 18 years, the company said.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Innoviva to Sell Basilea Pharmaceutica's MRSA Antibiotic Zevtera in US Under Exclusive Deal</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nInnoviva to Sell Basilea Pharmaceutica's MRSA Antibiotic Zevtera in US Under Exclusive Deal\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2024-12-16 21:40</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Innoviva (INVA) unit Innoviva Specialty <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> said Monday it signed an exclusive licensing and distribution deal with Basilea Pharmaceutica for US marketing rights to the antibiotic Zevtera or ceftobiprole.</p><p>The company, which plans to launch Zevtera in the US by mid-2025, said it will pay Basilea $4 million upfront, with additional royalties and sales milestones.</p><p>Basilea said in a separate statement that it expects to receive sales milestones of up to $223 million.</p><p>Zevtera, approved by the US Food and Drug Administration in April, is the only cephalosporin cleared for treating methicillin-resistant Staphylococcus aureus, or MRSA, bloodstream infections and endocarditis in adults.</p><p>The drug is also approved for other bacterial infections, including skin infections in adults and pneumonia in patients aged three months to 18 years, the company said.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"INVA","symbol_name":"Innoviva, Inc.","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2491962606","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2491962606","pubTimestamp":1734356416,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Innoviva  unit Innoviva Specialty Therapeutics said Monday it signed an exclusive licensing and distribution deal with Basilea Pharmaceutica for US marketing rights to the antibiotic Zevtera or ceftobiprole.The company, which plans to launch Zevtera in the US by mid-2025, said it will pay Basilea $4 million upfront, with additional royalties and sales milestones.Basilea said in a separate statement that it expects to receive sales milestones of up to $223 million.Zevtera, approved by the US Food and Drug Administration in April, is the only cephalosporin cleared for treating methicillin-resistant Staphylococcus aureus, or MRSA, bloodstream infections and endocarditis in adults.The drug is also approved for other bacterial infections, including skin infections in adults and pneumonia in patients aged three months to 18 years, the company said.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"INVA":"Innoviva, Inc.","BK4007":"制药"},"translate_title":"Innoviva将根据独家协议在美国销售Basilea Pharmaceutica的MRSA抗生素Zevtera","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"INVA":1},"content_text":"Innoviva (INVA) unit Innoviva Specialty Therapeutics said Monday it signed an exclusive licensing and distribution deal with Basilea Pharmaceutica for US marketing rights to the antibiotic Zevtera or ceftobiprole.The company, which plans to launch Zevtera in the US by mid-2025, said it will pay Basilea $4 million upfront, with additional royalties and sales milestones.Basilea said in a separate statement that it expects to receive sales milestones of up to $223 million.Zevtera, approved by the US Food and Drug Administration in April, is the only cephalosporin cleared for treating methicillin-resistant Staphylococcus aureus, or MRSA, bloodstream infections and endocarditis in adults.The drug is also approved for other bacterial infections, including skin infections in adults and pneumonia in patients aged three months to 18 years, the company said.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.32.1","shortVersion":"4.32.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2491962606"}